The Application Effect of Xuezhikang Capsule Combined with Pravastatin Sodium Tablets on Elderly Patients with Chronic Heart Failure after Acute Myocardial Infarction and Its Impact on Neuroendocrine Factors

Abstract

Abstract: Objective To explore the application effect of Xuezhikang Capsule combined with pravastatin sodium tablets on elderly patients with chronic heart failure after acute myocardial infarction and its impact on neuroendocrine factors. Methods Eighty patients with chronic heart failure after acute myocardial infarction admitted to Chuiyangliu Hospital in Beijing from June 2022 to April 2023 were selected for study. They were divided into three groups by lot drawing, namely, control group (n=30), observation group A (n=25) and observation group B (n=25). After giving conventional treatment to the control group, observe the patients in group A to add pravastatin sodium tablets on the basis of the control group, and increase the oral administration of Xuezhikang Capsule on the basis of observation group A. The clinical efficacy of the three groups of patients was compared, and the levels of B-type natriuretic peptide (BNP), plasma renin (PRA), Aldosterone (ALD), and angiotensin Ⅱ (Ang Ⅱ) related endocrine factors were compared with the changes of left ventricular Ejection fraction (LVEF), left ventricular end systolic volume (LVESV), and left ventricular end diastolic volume (LVEDV) related cardiac function indexes. Results The total effective rate of Group B was significantly higher than that of the control group and Group A, and Group A was higher than the control group (P<0.05); After treatment, the levels of BNP, PRA, ALD, and Ang II in the three groups of patients decreased, and the observation group B was lower than the control group and observation group A, while the observation group A was lower than the control group (P<0.05); After treatment, the LVEF of the three groups of patients increased, and Group B was observed to be higher than the control group and Group A. Group A was observed to be higher than the control group, while LVESV and LVEDV decreased. Group B was observed to be lower than the control group and Group A, and Group A was observed to be lower than the control group (P<0.05). Conclusion The combination of Xuezhikang Capsule and Pravastatin Sodium Tablets has a significant therapeutic effect on elderly patients with chronic heart failure after acute myocardial infarction, and can reduce the levels of neuroendocrine factors and improve heart function, which is worthy of clinical application.

Key words: Xuezhikang Capsule, pravastatin sodium tablets, acute myocardial infarction, chronic heart failure, neuroendocrine factors

CLC Number:

R592

LIU Yan, HOU Cong. The Application Effect of Xuezhikang Capsule Combined with Pravastatin Sodium Tablets on Elderly Patients with Chronic Heart Failure after Acute Myocardial Infarction and Its Impact on Neuroendocrine Factors[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(9): 28-31.

References

[1] 吴家刚,郑睦锐.2013—2017年广州市急性心肌梗死流行特征及趋势分析[J].华南预防医学,2020,46(1):38-42.
[2] 张越强,刘凡凡,陈还珍.沙库巴曲缬沙坦在心力衰竭及急性心肌梗死中临床应用的研究进展[J].中西医结合心脑血管病杂志,2023,21(3):450-453.
[3] 王国强,伦令祝,李鹏宇.自拟心通方辅助西医治疗急性心肌梗死后心力衰竭疗效及对心功能、炎症标志物水平的影响[J].安徽医药,2023,27(2):392-396.
[4] 彭婉慧,李奇,李欣欣,等.血脂康胶囊对不同体质类型急性缺血性脑卒中患者低密度脂蛋白亚型的影响[J].广西医学,2022,44(8):843-846,856.
[5] 蒋世亮,季晓平,张运.美国心脏病学会和美国心脏病协会发布关于ST段抬高型急性心肌梗死治疗指南(2004年修订版)[J].中华医学杂志,2005,85(1):62-64.
[6] 卢永昕. 慢性心力衰竭的临床评估和治疗原则——2005ACC/AHA慢性心力衰竭治疗指南简介[J].临床心血管病杂志,2005,21(11):691-695.
[7] 中华中医药学会慢性心力衰竭中医诊疗指南项目组.慢性心力衰竭中医诊疗指南(2022年)[J].中医杂志,2023,64(7):743-756.
[8] 张玉霞,陈浩,张鸿,等.血浆Periostin蛋白,嗜铬粒蛋白A,可溶性Sema4D水平与扩张型心肌病慢性心力衰竭病人心功能分级和心室重构的相关性分析[J].安徽医药,2021,25(12):2514-2518.
[9] 张富成,陈康玉,王齐,等.急性心肌梗死后患者院内心力衰竭的临床特征与分析[J].中国临床保健杂志,2023,26(2):260-264.
[10] 李辉,王永来,尚晓明.芪参宁心方治疗急性心肌梗死后顽固性心力衰竭61例[J].环球中医药,2023,16(2):332-335.
[11] 丁小琼,王清传,王元标,等.不同剂量万古霉素对慢性心力衰竭大鼠心功能、肾功能及神经内分泌因子的影响及其血药浓度变化[J].广西医学,2023,45(5):567-574,579.
[12] 杜晔,马学淼,韩宇博,等.益气温阳、活血利水法对慢性心力衰竭患者心功能及神经内分泌相关指标的影响研究[J].临床和实验医学杂志,2023,22(8):809-813.
[13] 钱晶,顾顺忠,陆洋,等.沙库巴曲缬沙坦钠对慢性心力衰竭患者sST2、hFABP、Lp-PLA2水平及神经内分泌激素的影响[J].中国病案,2023,24(1):95-99.
[14] 唐思琴,郭冰,刘丽芝,等.心康冲剂对慢性心力衰竭大鼠去甲肾上腺素转运蛋白及交感神经系统的影响[J].湖南中医药大学学报,2023,43(1):34-39.
[15] 牛超峰,张立晶,张玲霞,等.血脂康胶囊联合耳穴压丸对颈动脉粥样硬化患者血脂、炎症因子及颈动脉斑块的影响[J].现代中西医结合杂志,2022,31(13):1833-1837.
[16] 叶芬,俞子恒,杨江华,等.血脂康胶囊辅助治疗冠状动脉粥样硬化性心脏病的疗效及对血管内皮功能、心脏功能的影响[J].中华中医药学刊,2022,40(4):180-183.